Page last updated: 2024-12-05

methenamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methenamine: An anti-infective agent most commonly used in the treatment of urinary tract infections. Its anti-infective action derives from the slow release of formaldehyde by hydrolysis at acidic pH. (From Martindale, The Extra Pharmacopoeia, 30th ed, p173) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

hexamethylenetetramine : A polycyclic cage that is adamantane in which the carbon atoms at positions 1, 3, 5 and 7 are replaced by nitrogen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4101
CHEMBL ID1201270
CHEBI ID6824
SCHEMBL ID33785
MeSH IDM0013566

Synonyms (269)

Synonym
MLS002207085
hexamine
preparation af
resotropin
herax uts
antihydral
nsc-26346
formin (heterocycle)
hexamethylenetetramine, tech.
hexamine (heterocycle)
uramin
nsc26346
formin (the heterocyclic compound)
methenamin
urodeine
heterin
100-97-0
aminoform
hexamethyleneamine
hexasan
cystogen
xametrin
ammoform
hexilmethylenamine
hexaform
methenamine
uritone
ekagom h
aminoformaldehyde
hexaloids
hexa-flo-pulver
urotropin
hexamethylenetetraamine
urotropine
methamin
uratrine
formin
1,5,7-tetraazaadamantane
formamine
aceto hmt
duirexol
hexamethylenetetramine
ammonioformaldehyde
component of uro-phosphate
cystamin
hexamethylentetramin
wln: t66 b6 a b-c 1b i bn dn fn hntj
1,5,7-tetraazatricyclo[3.3.1.13,7]decane
KBIO1_000322
DIVK1C_000322
hexamethylenetetramine (aliphatic)
1,3,5,7-tetraazatricyclo[3.3.1.13,7]decane
SPECTRUM_000991
uro-phosphate
PRESTWICK_79
1,3,5,7-tetraazaadamantane
hexamethylenamine
hmta
1,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane
CHEBI:6824 ,
hexaminum
hexamethylene tetramine
hexamethylentetraminum
HMT ,
methenaminum
metenamina
nsc-403347
nsc403347
IDI1_000322
BSPBIO_003380
SPECTRUM5_001603
1,3,5,7-tetraazatricyclo[3.3.1.1~3,7~]decane
inchi=1/c6h12n4/c1-7-2-9-4-8(1)5-10(3-7)6-9/h1-6h
methenaminum [inn-latin]
1,3,5,7-tetraazatricyclo (3.3.1.1(3,7))decane
vulkacit h 30
metenamina [inn-spanish]
hexamethylentetramin [german]
hexamethylenetetraminum
ccris 2297
hexa (vulcanization accelerator)
hexasan (van)
un1328
methenamine silver
hexamethylenetetramine [un1328] [flammable solid]
hsdb 563
nocceler h
nsc 26346
metramine
1,3,5,7-tetraazatricyclo(3.3.1.13,7)decane
hexamethylentetramine
einecs 202-905-8
s 4 (heterocycle)
nsc 403347
ai3-09611
1,3,5,7-tetraazatricyclo(3.3.1.1(sup 37))decane
epa pesticide chemical code 045501
sanceler h
methenamine [usan:inn]
esametilentetramina [italian]
1,3,5,7-tetraazatricyclo(3.3.1.1(sup 3,7))decane
hexamine silver
silver methenamine
caswell no. 482
hexamethylenetetramine, bioxtra
methenamine (usp/inn)
hexamine (jan)
hexamine (tn)
D00393
hexamethylenetetramine, acs reagent, >=99.0%
NCGC00094719-02
NCGC00094719-01
KBIO2_004039
KBIO3_002600
KBIOGR_001563
KBIOSS_001471
KBIO2_006607
KBIO2_001471
NINDS_000322
SPECTRUM3_001730
SPBIO_000753
SPECTRUM4_000872
SPECTRUM2_000827
SPECTRUM1500394
NCGC00094719-03
MLS001332361
smr000857139
MLS001332362
hexamethylenetetramine, reagentplus(r), 99%
HMS2091D08
hexamethylenetetramine, acs
1,3,5,7-tetraazatricyclo[3.3.1.13,7 ]decane
HMS501A04
FT-0669190
H0093
HMS1920L13
AKOS000120003
NCGC00094719-04
NCGC00094719-05
NCGC00094719-06
s 4
el 10 (corrosion inhibitor)
rhenogran hexa 80
hexamethylenetetramine [un1328] [flammable solid]
methenamine [usp:inn]
j50oix95qv ,
sanceler ht
unii-j50oix95qv
cohedur h 30
ec 202-905-8
heksa k
thixon 715b
esametilentetramina
hexa b
sanceler ht-po
el 10
hexamine superfine
nocceler h-po
ins no.239
CHEMBL1201270
e-239
ins-239
e239
NCGC00254463-01
dtxsid6020692 ,
NCGC00259155-01
tox21_300502
dtxcid00692
tox21_201606
tox21_113455
cas-100-97-0
nsc-757101
pharmakon1600-01500394
nsc757101
AE-641/00560026
HMS2233B09
CCG-40289
AKOS005169648
FT-0627024
methenamine [inci]
methenamine [who-dd]
methenamine [ep monograph]
methenamine [usp-rs]
methenamine [mi]
methenamine [hsdb]
methenamine [vandf]
methenamine [mart.]
hexamine [jan]
methenamine [usp monograph]
methenamine [inn]
1,3,5,7-tetraazatricyclo(3.3.1.1 sup(3,7))decane
S3139
HMS3371O15
HY-B0514
1,3,5,7-tetraazatricyclo[3.3.1.1?,?]decane
SCHEMBL33785
NCGC00094719-08
tox21_113455_1
hexamethylene-tetramine
1,3,5,7-tetraaza-tricyclo[3.3.1.1*3,7*]decane
1,3,5,7-tetraazatricyclo[3,3,1,13,7]decane
hexamethylene tetraamine
hexam-ethylenetetraamine
1,3,5,7-tetraaza-tricyclo[3.3.1.13,7]decane
1,3,5,7-tetraazatricyclo-[3.3.1.13,7]decane
uro-phosphate (salt/mix)
h.m.t.
1,3,5,7-tetraazatricyclo[3.3.1.1(sup 3,7)]decane
1,3,5,7-tetraazatricyclo-[3.3.1.1(3,7)]decane
vesaloin
cystex (salt/mix)
STR00289
1,3,5,7-tetraazatricyclo[3.3.1.1^{3,7}]decane
AB00052038_08
AB00052038_09
DB06799
metenamine
J-521456
J-000293
F2173-0429
hexamethylenetetramine, anhydrous, free-flowing, redi-dri(tm), acs reagent, >=99.0%
mfcd00006895
SR-05000002024-3
sr-05000002024
hexamethylenetetramine, saj first grade, >=98.5%
hexamethylenetetramine, jis special grade, >=99.0%
hexamethylenetetramine, analytical reference material
methenamine, united states pharmacopeia (usp) reference standard
HMS3652A05
SR-05000002024-1
hexamethylenetetramine, lr, >=99%
methenamine, european pharmacopoeia (ep) reference standard
hexamethylenetetramine, p.a., acs reagent, 99.0%
SBI-0051439.P003
HMS3715D17
grasselerator 102
carin
hexamethylamine
formaldehyde-ammonia 6:4
[16]-adamazane, inn
naphthamine
vulkacit h30
hexamethylentetramin(german)
urisol
hexamethylenetetramine, 8ci
Z362014242
SW199604-2
methenamine (mandelamine)
Q71969
BRD-K30114692-001-10-0
1,3,5,7-tetraazatricyclo[3.3.1.1{3,7}]decane
1,3,5,7-tetraazatricyclo[3.3.1.1,3,7]decane
EN300-16855
STL197471
1,3,5,7-tetrazatricyclo[3.3.1.13,7]decane
gtpl10913
urotropine 100 microg/ml in methanol
j01xx05
methenaminum (inn-latin)
methenamine (usp monograph)
methenamine (ep monograph)
metenamina (inn-spanish)
1,3,5,7-tetraazatricyclo(3.3.1.1(3,7))decane
metheneamine
methamine
urasal
methenamine (usp-rs)
methenamine (usp:inn)
methenamine (mart.)

Research Excerpts

Overview

Methenamine hippurate is an effective prophylactic agent against recurrent acute cystitis and has the advantage of not inducing cross resistance to conventional antibiotics. Methenamine is a polycyclic organic compound which release ammonia and formaldehyde at acid pH.

ExcerptReferenceRelevance
"Methenamine hippurate is a urinary antiseptic used as preventive treatment for recurrent urinary tract infections (UTIs) in some Scandinavian countries. "( Methenamine hippurate to prevent recurrent urinary tract infections in older women: protocol for a randomised, placebo-controlled trial (ImpresU).
Åhrén, C; Godycki-Cwirko, M; Groen, WG; Grude, N; Gunnarsson, R; Heltveit-Olsen, SR; Hertogh, CMPM; Hoye, S; Koning, HAM; Kowalczyk, A; Lindbaek, M; Platteel, TN; Snaebjörnsson Arnljots, E; Sundvall, PD; Verheij, TJM, 2022
)
3.61
"Methenamine hippurate is a useful alternative in long-term prophylaxis against recurrent urinary tract infections in girls."( Long-term prophylaxis with methenamine hippurate in girls with recurrent urinary tract infections.
Petersen, S, 1978
)
1.28
"Methenamine is a polycyclic organic compound which release ammonia and formaldehyde at acid pH."( Treatment of hyperhidrosis with topical methenamine.
Bergstresser, PR; Quero, R,
)
1.12
"Methenamine hippurate is an effective prophylactic agent against recurrent acute cystitis and has the advantage of not inducing cross resistance to conventional antibiotics."( Prevention of recurrent acute cystitis by methenamine hippurate: double blind controlled crossover long term study.
Cronberg, S; Hellsten, S; Henriksson, L; Persson, KM; Stenberg, P; Welin, CO, 1987
)
1.26

Treatment

ExcerptReferenceRelevance
"Oral treatment with methenamine-hippurate (MH) in patients with an indwelling catheter has been found to reduce the need of frequent catheter exchange and the number of symptomatic infections. "( Methenamine-hippurate and bacteriuria in the geriatric patient with a catheter.
Norrman, K; Scheynius, A; Wibell, L, 1980
)
2.03

Toxicity

ExcerptReferenceRelevance
"The toxic effects of modified endodontic sealers, Fillcanal, N-Rickert, FS, and Sealer 26, were assessed."( Cytotoxicity of some modified root canal sealers and their leachable components.
Araki, K; Barbosa, SV; Spångberg, LS, 1993
)
0.29
" Maximal protection against the toxic effects of HD (LC50) was found at 10 to 25 mM HMT."( Protection of A549 cells against the toxic effects of sulphur mustard by hexamethylenetetramine.
Hambrook, JL; Lindsay, CD, 1997
)
0.3
" Sulphur mustard ('mustard gas', HD) is a highly toxic chemical warfare agent which affects the skin and respiratory tract."( Protection of human upper respiratory tract cell lines against sulphur mustard toxicity by hexamethylenetetramine (HMT).
Andrew, DJ; Lindsay, CD, 1998
)
0.3
" AH26 had a severe cytotoxic effect whilst Topseal and AH-Plus showed a markedly lower toxic influence on the cells during the experimental period."( Cytotoxicity of three resin-based root canal sealers: an in vitro evaluation.
Beltes, P; Geromichalos, GD; Kortsaris, AH; Koulaouzidou, EA; Papazisis, KT, 1998
)
0.3
" The results obtained in this study showed the high cytotoxcity of the new AH Plus root canal sealer, which was shown to be equally or more toxic to the standard AH26 and Diaket materials."( Cytotoxic effect of four root filling materials.
Anić, I; Karlović, Z; Marsan, T; Miletić, I; Osmak, M; Pezelj-Ribarić, S, 2000
)
0.31
" Calcium hydroxide-based sealer was the least toxic sealer amongst the chemicals tested in both cultures."( Cytotoxicity of resin-, zinc oxide-eugenol-, and calcium hydroxide-based root canal sealers on human periodontal ligament cells and permanent V79 cells.
Chang, YC; Chou, MY; Huang, FM; Tai, KW, 2002
)
0.31
" Methenamine had few adverse side effects for patients."( Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: A single center, retrospective study.
Ho, B; Hollyer, I; Ison, MG; Varias, F, 2019
)
1.73

Compound-Compound Interactions

ExcerptReferenceRelevance
" DXR's encapsulation into pegylated liposomes and combination with HMTA, particularly when administered continuously, apparently reduced the difference in sensitivity to free DXR between the total and Q cell populations."( Usefulness of hexamethylenetetramine in combination with chemotherapy using free and pegylated liposomal doxorubicin in vivo, referring to the effect on quiescent cells.
Kashino, G; Kinashi, Y; Kono, K; Liu, Y; Masunaga, S; Nakamura, J; Ono, K; Suzuki, M; Tano, K; Watanabe, M; Yoshida, H, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" The method was applied to the dtermination of the bioavailability of methenamine hippurate in ten human volunteers."( Simultaneous determination of methenamine and formaldehyde in the urine of humans after methenamine administration.
Gollamudi, R; Meyer, MC; Straughn, AB,
)
0.65
" The effective combinations (L-TC + DOX, NAC + DOX, NAC + DMTU, NAC + HMT, NC + DOX) combined agents, reducing the bioavailability of the mustard with compounds possibly acting on the consequences of alkylation."( Efficient protection of human bronchial epithelial cells against sulfur and nitrogen mustard cytotoxicity using drug combinations.
Baeza-Squiban, A; Calvet, J; Marano, F; Rappeneau, S, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The mechanism of action, spectrum of antimicrobial activity, pharmacokinetics, adverse effects, therapeutic use, and dosage of methenamine hippurate and methenamines mandelate are reviewed. Urinary pH was assessed in relation to the dosage of ascorbic acid.

ExcerptRelevanceReference
" Urinary pH was assessed in relation to the dosage of ascorbic acid, duration of therapy, formulation, and dosing intervals for ascorbic acid and methenamine."( Appraisal of ascorbic acid for acidifying the urine of methenamine-treated geriatric patients.
Bell, CJ; Lamy, PP; Naccarto, DV, 1979
)
0.71
"The mechanism of action, spectrum of antimicrobial activity, pharmacokinetics, adverse effects, therapeutic use, and dosage of methenamine hippurate and methenamine mandelate are reviewed."( Drug therapy reviews: methenamine mandelate and methenamine hippurate.
Alvarez, S; Gleckman, R; Joubert, DW; Matthews, SJ, 1979
)
0.78
" No adverse reactions were recorded with the dosage used."( Long-term acidification of urine in patients treated for infected renal stones.
Tiselius, HG; Wall, I, 1990
)
0.28
"Dissolution profiles were determined for nine methenamine, 14 nitrofurantoin, and six chlorothiazide dosage forms using a dissolution simulator."( In vivo-in vitro correlations with a commercial dissolution simulator. I: Methenamine, nitrofurantoin, and chlorothiazide.
Meyer, MC; Yau, MK, 1981
)
0.75
" In order to know the DNA-damaging capacity of positive samples, the dose-response curves were prepared by carrying out the assays at various doses, and minimal inhibition concentration (MIC) for H 17 and M 45 was obtained from these curves by extrapolation."( [Mutagenicity of organic rubber additives].
Ishizaki, M; Ueno, S, 1984
)
0.27
" The following dosage forms were evaluated: a tablet of methenamine base, a methenamine hippurate tablet, and eight products containing methenamine mandelate, including six enteric-coated tablets, a suspension, and a granule dosage form."( Urinary excretion of methenamine and formaldehyde: evaluation of 10 methenamine products in humans.
Gollamudi, R; Meyer, MC; Straughn, AB, 1981
)
0.83
" The calculated alveolar molar dosage of phosgene was 9 µmol/kg."( Attempts to counteract phosgene-induced acute lung injury by instant high-dose aerosol exposure to hexamethylenetetramine, cysteine or glutathione.
Hai, CX; Pauluhn, J, 2011
)
0.37
" Micropipettes were used for delivering the exact dosage of the allergen."( Patch testing with 2.0% (0.60 mg/cm 2) formaldehyde instead of 1.0% (0.30 mg/cm 2) detects significantly more contact allergy.
Aalto-Korte, K; Agner, T; Andersen, KE; Bruze, M; Giménez-Arnau, AM; Gonçalo, M; Goossens, A; Johansen, JD; Le Coz, CJ; Maibach, HI; Pontén, A; Rustemeyer, T; White, IR, 2013
)
0.39
" Based on information on drug, dosage and indication, we assessed whether the use of antibiotics for the treatment of UTIs was in accordance with the National Guidelines for the Use of Antibiotics in Primary Care."( Antibiotic use and infections in nursing homes.
Alberg, T; Bentele, H; Blix, HS; Eriksen, HM; Holen, Ø; Lindbæk, M, 2017
)
0.46
" Choice of drug, dosage and microbiological testing when treating lower UTIs was not always in accordance with the national guidelines."( Antibiotic use and infections in nursing homes.
Alberg, T; Bentele, H; Blix, HS; Eriksen, HM; Holen, Ø; Lindbæk, M, 2017
)
0.46
"The survey indicates that compliance with the national guidelines when treating lower UTIs could be improved with regard to the choice of drug, dosage and microbiological testing."( Antibiotic use and infections in nursing homes.
Alberg, T; Bentele, H; Blix, HS; Eriksen, HM; Holen, Ø; Lindbæk, M, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
AZO Urinary Tract Defense -- 24 TabletsAZOVitamins & SupplementsMethenamine2024-11-29 10:47:42

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
polycyclic cageA polycyclic compound having the shape of a cage.
polyazaalkaneAny azaalkane in which two or more carbons in the chain are replaced by nitrogen.
tetramineAny polyamine that contains four amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.48660.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency54.15040.003041.611522,387.1992AID1159552
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.77160.000229.305416,493.5996AID743069
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency21.73600.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency4.25270.023723.228263.5986AID743223
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency3.16230.004611.374133.4983AID624297
Cellular tumor antigen p53Homo sapiens (human)Potency0.99160.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (68)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1808090Stability in human gut microbes assessed as half life by LC-MS analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1808091Drug metabolism in mini gut model assessed as metabolite formation by LC-MS/MS analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1134606Et2O-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1808092Drug metabolism in human gut microbes assessed as metabolite formation by LC-MS/MS analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID1808089Stability of compound in mini gut model assessed as half life by LC-MS analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1134605Oil-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,044)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990610 (58.43)18.7374
1990's160 (15.33)18.2507
2000's130 (12.45)29.6817
2010's105 (10.06)24.3611
2020's39 (3.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 80.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index80.98 (24.57)
Research Supply Index7.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index152.53 (26.88)
Search Engine Supply Index2.09 (0.95)

This Compound (80.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials69 (6.19%)5.53%
Reviews47 (4.22%)6.00%
Case Studies46 (4.13%)4.05%
Observational0 (0.00%)0.25%
Other952 (85.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis [NCT03379389]Phase 4284 participants (Actual)Interventional2018-03-31Completed
Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs [NCT03077711]Phase 492 participants (Actual)Interventional2016-06-30Completed
Probiotics/Lactobacillus as a Prophylactic Aid in Recurrent Bacterial Cystitis in Women. A Randomized, Prospective, Double-Blinded, Placebo Controlled, Multi-Center Study. [NCT00781625]120 participants (Anticipated)Interventional2008-10-31Recruiting
The Efficacy and Cost-effectiveness of a 24-hour Course of metheNamine Hippurate for Preventing Post-Operative Urinary Tract Infection [NCT02358993]201 participants (Actual)Interventional2014-12-31Completed
Methenamine Hippurate With Cranberry Capsules Versus Cranberry Capsules Alone for UTI Prevention in a Short-term Indwelling Foley Catheter Population After Urogynecological Surgery: A Double-Blinded Randomized Controlled Trial [NCT03818321]Phase 2185 participants (Actual)Interventional2019-06-17Completed
A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain [NCT05658874]Phase 380 participants (Anticipated)Interventional2022-12-01Recruiting
Phase III, Prospective, Multicenter, Single-blind, Randomized, Superiority to Evaluate the Efficacy and Safety of Methenamine Association 250mg + Methylthioninium Chloride 20 mg Compared to Phenazopyridine 100 mg in Symptomatic Control of Dysuria [NCT01657448]Phase 3316 participants (Actual)Interventional2016-06-27Completed
The Efficacy and Effect of Methenamine Hippurate in a Non-antibiotic, Multimodal Approach to UTI Prevention [NCT03996057]Phase 40 participants (Actual)Interventional2018-06-20Withdrawn(stopped due to "Project canceled due to PI leaving institution, staff changes and COVID~Project canceled for other reason , describe: - Due to staff changes and COVID~Project canceled due to PI leaving, staff changes and COVID")
The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing Due to New Episodes of Urinary Tract Infections (UTI) in Elderly Women With Recurrent UTI - a Triple- Blinded, Randomized Placebo-controlled Phase IV Study [NCT04077580]Phase 4400 participants (Anticipated)Interventional2019-11-01Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02358993 (5) [back to overview]Antibiotic Resistance of Culture-positive Symptomatic UTI
NCT02358993 (5) [back to overview]Number of Participants With Culture-positive Symptomatic UTI
NCT02358993 (5) [back to overview]Rate of UTI Consistent With NHSN Criteria
NCT02358993 (5) [back to overview]Treatment of Clinically Suspected UTI - Per Protocol
NCT02358993 (5) [back to overview]Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis
NCT03077711 (5) [back to overview]Morisky Medication Adherence Survey
NCT03077711 (5) [back to overview]Number of Infections
NCT03077711 (5) [back to overview]Recurrent UTI
NCT03077711 (5) [back to overview]Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI
NCT03077711 (5) [back to overview]Bacterial Infection Prevalence and Types
NCT03818321 (1) [back to overview]Incidence of Urinary Track Infection (UTI)

Antibiotic Resistance of Culture-positive Symptomatic UTI

All patients who submit urine cultures that are positive will have sensitivities performed as per standard care. The prevalence of bacterial species and sensitivities will be collected (NCT02358993)
Timeframe: 3 weeks post-operative

InterventionParticipants (Count of Participants)
Methenamine0
Ciprofloxacin0

[back to top]

Number of Participants With Culture-positive Symptomatic UTI

All patients will be encouraged to submit urine cultures prior to treatment, but this is not always possible. Amongst patients who undergo urine culture as part of standard of care for UTI, the rate of positive cultures will be identified. (NCT02358993)
Timeframe: 3 weeks post-operative

InterventionParticipants (Count of Participants)
Methenamine5
Ciprofloxacin4

[back to top]

Rate of UTI Consistent With NHSN Criteria

We plan to analyze the prevalence of UTI in this population that meet the definitions of symptomatic UTI and catheter-associated UTI according to the National Healthcare Safety Network criteria. (NCT02358993)
Timeframe: 3 weeks post-operative

InterventionParticipants (Count of Participants)
Methenamine10
Ciprofloxacin6

[back to top]

Treatment of Clinically Suspected UTI - Per Protocol

This is defined as any symptomatic UTI requiring treatment with antibiotics as determined by the development of 2 or more of the following symptoms, in the absence of vaginal symptoms: urinary frequency; urinary urgency; dysuria; fever over 38oC/100.4oF; suprapubic, flank, or back pain; and/or chills. (NCT02358993)
Timeframe: 3 weeks post-operative

InterventionParticipants (Count of Participants)
Methenamine12
Ciprofloxacin12

[back to top]

Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis

This is defined as any symptomatic UTI requiring treatment with antibiotics as determined by the development of 2 or more of the following symptoms, in the absence of vaginal symptoms: urinary frequency; urinary urgency; dysuria; fever over 38oC/100.4oF; suprapubic, flank, or back pain; and/or chills. (NCT02358993)
Timeframe: 3 weeks post-operative

InterventionParticipants (Count of Participants)
Methenamine13
Ciprofloxacin12

[back to top]

Morisky Medication Adherence Survey

Morisky Medication Adherence Scale-8 (MMAS-8). Patient tolerability of medications using a tolerability survey. Minimum and maximum scores are 0 and 8 respectively. 0 means no adherence and 8 is maximal adherence. Low adherence corresponds to a score less than 6, medium adherence is between 6 and <8, and 8 is high adherence. (NCT03077711)
Timeframe: up to 12 months

Interventionunits on a scale (Mean)
Patients With Recurrent UTIs Arm 17.28
Patients With Recurrent UTIs Arm 26.94

[back to top]

Number of Infections

The number of infections at a 12 month follow up time period as defined by symptoms and positive urine culture. (NCT03077711)
Timeframe: up to 12 months

Interventionurinary tract infections (Mean)
Patients With Recurrent UTIs Arm 11.5
Patients With Recurrent UTIs Arm 21.6

[back to top]

Recurrent UTI

The number of patient who had a recurrence of UTI within 12 months (NCT03077711)
Timeframe: up to 12 months

InterventionParticipants (Count of Participants)
Patients With Recurrent UTIs Arm 128
Patients With Recurrent UTIs Arm 228

[back to top]

Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI

Patients will be advised to follow up with any symptoms of a recurrence or at 6 and 12 month intervals if symptom-free. (NCT03077711)
Timeframe: up to 12 months

Interventiondays (Mean)
Patients With Recurrent UTIs Arm 1101
Patients With Recurrent UTIs Arm 2119

[back to top]

Bacterial Infection Prevalence and Types

Urine cultures and sensitivities for positive urine cultures (NCT03077711)
Timeframe: up to 12 months

,
Interventioninfections (Number)
Escherichia coliKlebsiella pneumoniaEnterococcus faecalisExtended spectrum beta lactamase Escherichia coliOther bacteriaStrains pan sensitive to all antibioticsStrains resistant to trimethoprimStrains resistant to abx other than trimethoprim
Patients With Recurrent UTIs Arm 14311361555810
Patients With Recurrent UTIs Arm 25069912203029

[back to top]

Incidence of Urinary Track Infection (UTI)

Incidence of UTIs will be diagnosed at one week post-op visit. (NCT03818321)
Timeframe: From surgery to one week post-op visit, approximately 1 week post surgery

InterventionParticipants (Count of Participants)
Methenamine Hippurate With Cranberry62
Placebo With Cranberry71

[back to top]